KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Invested Capital (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Invested Capital for 16 consecutive years, with $121.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Invested Capital rose 274.76% year-over-year to $121.3 million, compared with a TTM value of $121.3 million through Dec 2025, down 24.64%, and an annual FY2024 reading of $160.9 million, up 172.92% over the prior year.
  • Invested Capital was $121.3 million for Q3 2025 at Alnylam Pharmaceuticals, down from $371.4 million in the prior quarter.
  • Across five years, Invested Capital topped out at $1.3 billion in Q2 2021 and bottomed at -$408.1 million in Q2 2023.
  • Average Invested Capital over 5 years is $326.7 million, with a median of $121.3 million recorded in 2025.
  • The sharpest move saw Invested Capital tumbled 147.8% in 2023, then surged 12209.26% in 2025.
  • Year by year, Invested Capital stood at $1.3 billion in 2021, then crashed by 112.52% to -$158.2 million in 2022, then tumbled by 39.45% to -$220.6 million in 2023, then soared by 172.92% to $160.9 million in 2024, then dropped by 24.64% to $121.3 million in 2025.
  • Business Quant data shows Invested Capital for ALNY at $121.3 million in Q3 2025, $371.4 million in Q2 2025, and $233.5 million in Q1 2025.